ArticleJournal of experimental & clinical cancer research : CR2025
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors.
Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) is a significant global health challenge, with 2% of cases fuelled by RET rearrangements. RET inhibitors (RETi) have revolutionized treatment for these patients, but resistance remains an important clinical challenge limiting therapy effectiveness. This study investigated the mechanisms underlying resistance to RETi.
methodsNSCLC cells were exposed to increasing doses of RETi (pralsetinib/BLU-667 and selpercatinib/LOXO-292) to generate resistant cells. RNA-Sequencing analysis identified differentially expressed genes in resistant versus sensitive cells, followed by in vitro and in vivo functional assays to explore novel therapeutic strategies. Additionally, tumor biopsies from RET-rearranged NSCLC patients who exhibited cancer progression on RET inhibitor therapy were analyzed.
resultsRNA-sequencing analysis revealed the upregulation of the EGFR signaling pathway and hyperactivation of AP1 complex members in resistant cells compared to sensitive cells. Silencing of EGFR and AP1 complex members significantly reversed drug resistance, whereas EGFR overexpression reduced the sensitivity of parental Lc2/AD cells to RET inhibitors. Furthermore, the combination of RET and EGFR inhibitors showed synergistic antitumor activity in vitro and hindered tumor growth in mouse models with resistant cell xenografts. Notably, we observed a significant increase in EGFR expression in tumor biopsies from NSCLC patients treated with RET inhibitors who experienced disease progression, further validating the clinical relevance of our findings.
conclusionsThis study elucidates EGFR's role in mediating resistance to RET inhibitors in NSCLC patients. These findings offer insights into therapeutic adaptation and explore personalized combinations of RET and EGFR inhibitors for improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.